Welcome to LookChem.com Sign In|Join Free

CAS

  • or

65069-55-8

Post Buying Request

65069-55-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

65069-55-8 Usage

Description

1-(3,4-Methylenedioxyphenyl)-2-thiourea, a chemical compound with the molecular formula C9H9N3O2S, is a derivative of phenylthiourea. It is recognized for its ability to form stable complexes with various metal ions and has been studied for its potential pharmaceutical applications, particularly in the treatment of cancer and other diseases. As a common building block in organic chemistry, it is utilized in the synthesis of various heterocyclic compounds. Its stable and non-toxic nature makes it a popular choice for research and laboratory applications.

Uses

Used in Pharmaceutical Applications:
1-(3,4-Methylenedioxyphenyl)-2-thiourea is used as a precursor in the synthesis of pharmaceutical compounds for the treatment of cancer and other diseases. Its potential medicinal properties are being explored due to its ability to interact with metal ions, which may contribute to its therapeutic effects.
Used in Chemical Reactions:
As a reagent, 1-(3,4-Methylenedioxyphenyl)-2-thiourea is used in various chemical reactions, facilitating the synthesis of other compounds. Its versatility in forming stable complexes with metal ions makes it a valuable component in these processes.
Used in Organic Chemistry:
1-(3,4-Methylenedioxyphenyl)-2-thiourea is used as a building block in the synthesis of heterocyclic compounds, contributing to the development of new organic molecules with potential applications in various fields.
Used in Research and Laboratory Applications:
Due to its stable and non-toxic nature, 1-(3,4-Methylenedioxyphenyl)-2-thiourea is a popular choice for research and laboratory applications, where it is used in experiments and as a component in the development of new chemical processes and compounds.

Check Digit Verification of cas no

The CAS Registry Mumber 65069-55-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,0,6 and 9 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 65069-55:
(7*6)+(6*5)+(5*0)+(4*6)+(3*9)+(2*5)+(1*5)=138
138 % 10 = 8
So 65069-55-8 is a valid CAS Registry Number.
InChI:InChI=1/C8H8N2O2S/c9-8(13)10-5-1-2-6-7(3-5)12-4-11-6/h1-3H,4H2,(H3,9,10,13)

65069-55-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 1,3-benzodioxol-5-ylthiourea

1.2 Other means of identification

Product number -
Other names 3,4-Methylenedioxyphenylthiourea

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:65069-55-8 SDS

65069-55-8Relevant articles and documents

Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase

Zhu, Junsheng,Han, Le,Diao, Yanyan,Ren, Xiaoli,Xu, Minghao,Xu, Liuxin,Li, Shiliang,Li, Qiang,Dong, Dong,Huang, Jin,Liu, Xiaofeng,Zhao, Zhenjiang,Wang, Rui,Zhu, Lili,Xu, Yufang,Qian, Xuhong,Li, Honglin

, p. 1123 - 1139 (2015/03/04)

Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.

Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors

Vogt, Dominik,Weber, Julia,Ihlefeld, Katja,Brüggerhoff, Astrid,Proschak, Ewgenij,Stark, Holger

supporting information, p. 5354 - 5367 (2014/12/11)

Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole class of SphK inhibitors. Potent inhibitors have been discovered through a series of modifications using the known SKI-II scaffold to define structure-activity relationships. We identified N-(4-methylthiazol-2-yl)-(2,4′-bithiazol)-2′-amine (24, ST-1803; IC50values: 7.3 μM (SphK1), 6.5 μM (SphK2)) as a promising candidate for further in vivo investigations and structural development.

Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors

Wilson, Kenneth J.,Illig, Carl R.,Subasinghe, Nalin,Hoffman, James B.,Jonathan Rudolph,Soll, Richard,Molloy, Christopher J.,Bone, Roger,Green, David,Randall, Troy,Zhang, Marie,Lewandowski, Frank A.,Zhou, Zhao,Sharp, Celia,Maguire, Diane,Grasberger, Bruce,DesJarlais, Renee L.,Spurlino, John

, p. 915 - 918 (2007/10/03)

The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino-1,3-thiazolyl]-thiophene-2-carboxamidines is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 65069-55-8